Immune thrombotic thrombocytopenic purpura (iTTP) is an acute, rare life-threatening condition associated with antibodies to ADAMTS13, resulting in severe enzyme deficiency, failure of von Willebrand factor (VWF) cleavage, excess platelet-VWF binding and microthrombi formation, resulting in multi-organ damage. iTTP is an immune-mediated condition and antibodies to ADAMTS13 are polyclonal.1,2 Despite this, and as replicated by a number of groups, nearly 100% of patients demonstrate a specific target region of antibody binding to the spacer domain in the N terminal region of the metalloprotease, ADAMTS13.3-7 Antibodies can be detected in other ADAMTS 13 domains, typically the TSP 2-8 regions or CUB domains, but to a lesser degree than spacer domain antibodies. Furthermore, spacer antibodies are more likely to inhibit ADAMT13 enzyme activity, as opposed to antibodies in the C terminal region of ADAMTS13, which result in increased ADAMTS13 clearance.8
It has been suggested that a possible therapeutic strategy for iTTP would be an ADAMTS13 variant that would prevent antibody binding within the pathogenic region of the spacer domain. As iTTP is a polyclonal antibody response, more than one epitope may need to be considered.
In the current issue of Haematologica, Graça and colleagues present a detailed description of the influence of the epitope (R568/F592/R660/Y661/Y665 [RFRYY]),9 within the spacer domain, the predominant site for autoantibody binding. The capacity for ADAMTS13 to cleave VWF with full-length mutants was reduced in varying amounts. The impact of the variants on autoantibody binding was assessed and compared to that of wildtype ADAMTS13. The comprehensive narrative concludes that non-conservative and alanine modifications of residues RFRYY, within exosite 3 of the spacer domain, were superior in preventing autoantibody binding. Importantly, selected ADAMTS13 variants maintained VWF cleavage mediated by the metalloprotease.
The spacer domain, comprising 130 amino acids, is between a cysteine-rich region and the TSP-2 repeat domain. The region is important and has two major effects. First, the binding to VWF, which is critical in ADAMTS13-mediated cleavage. The importance of spacer domain-mediated cleavage is verified by the resulting proteolytic activity involving the MDTCS compared to MDTC variants. Second, exosite 3, within the spacer domain, contains a cluster of hydrophobic residues. This specific exosite is critical in binding to the A2 region of VWF, but it is also the major epitope for ADAMTS13 autoantibodies.
Residues making up exosite 3 in the spacer domain of ADAMTS13 include Arg660, Tyr661, Tyr665,7 Arg568 and Phe592.10 Conservative substitution variants involve replacement of an amino acid within these residues but achieving comparable biochemical properties. A further effect of manipulation of this region is a gain-of-function ADAMTS13 variant. The effect of the gain-of-function variant, previously described, is resistance to ADAMTS13 autoantibodies and increased ADAMTS13 activity.11 Other variants have been developed, such as alanine modifications, which resulted in reduced ADAMTS13 autoantibody binding but also diminished ADAMTS13 cleavage of VWF.
In their study published in this issue of Haematologica, Graça and colleagues generated 42 ADAMTS13 variants, introduced into a full-length ADAMTS13 spacer exosite 3 region. The variants included the gain-of-function fragment, truncated wild-type MDTCS and MDTSC 5x Ala variants as well as conservative, semi-conservative and non-conservative substitutions with asparagine and alanine amino acids. Initially, samples from patients were examined for autoantibody binding against these developed variants, which were compared to wild-type ADAMTS13. Concurrently, each variant was analyzed for its ability to cleave VWF.
Results re-confirmed the predominant binding of ADAMTS13 autoantibodies to the exosite 3 region of the spacer, but antibody binding to the CUB and TSP 2-8 domains was also detected. The ability of the selection of variant ADAMTS13 to resist ADAMTS13 antibody was explored.
The conservative mutants had comparable autoantibody binding, but semi-conservative variants had reduced antibody binding compared to the wild-type spacer domain of ADAMTS13. Variants containing alanine and, to a lesser extent, asparagine were the most successful at preventing ADAMTS13 antibody binding. The gain-of-function mutation only achieved a small reduction in autoantibody binding. However, the 5x Ala full-length mutant (AAAAA) had the best effect in preventing autoantibody binding. Therefore, replacing the spacer epitope with asparagine or alanine amino acids had the greatest influence in averting ADAMTS13 antibodies from binding. The variants were compared to wild-type ADAMTS 13, assessing their ability to cleave VWF. In all the cases, cleavage of VWF was reduced in comparison to the wild-type protein. However, the greatest cleavage was noted in those with conservative and some of the semi-conservative mutants. Single alanine and asparagine changes were associated with the highest ADAMTS13 cleavage activity (Figure 1). VWF cleavage was further confirmed using recombinant VWF in multimeric gels. In general, mutations associated with the lowest ADAMTS13 cleavage activity demonstrated greater antibody resistance.
The three aromatic residues rather than the two arginine residues of exosite 3 in the spacer domain appear to have greater importance in ADAMTS 13 antibody binding. The greatest influence was noted with cumulative mutations of the aromatic residues, demonstrating the maximum effect in preventing ADAMTS13 autoantibody binding, which is achieved by re-presenting epitope loops, lowering the surface charge and reducing surface size.9
Current therapy for TTP aims to replace ADAMTS13, via plasma exchange and immunosuppression to remove autoantibodies to ADAMTS13. The main therapeutic modalities used are steroids and rituximab. Their role in reducing IgG antibody levels has been well described in both the treatment of acute TTP12 and as prophylaxis,13,14 usually resulting in normalization of ADAMTS13 activity. The importance of the work by Graca et al. is the detailed demonstration and confirmation that development of ADAMTS13 variants could be used to overcome the antibody response in iTTP, preventing autoantibodies to ADAMTS13 from binding to exosite 3 of the spacer domain but ensuring residual ADAMTS13 cleavage activity. There may be a role for these variants in future care of patients, conquering the immunological consequence of ADAMTS13 antibodies.
- Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001; 14(2):437-454. https://doi.org/10.1053/beha.2001.0142PubMedGoogle Scholar
- Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998; 339(22):1585-1594. https://doi.org/10.1056/NEJM199811263392203PubMedPubMed CentralGoogle Scholar
- Klaus C, Plaimauer B, Studt JD. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004; 103(12):4514-4519. https://doi.org/10.1182/blood-2003-12-4165PubMedGoogle Scholar
- Luken BM, Kaijen PH, Turenhout EA. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006; 4(11):2355-2364. https://doi.org/10.1111/j.1538-7836.2006.02164.xPubMedGoogle Scholar
- Zheng XL, Wu HM, Shang D. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010; 95(9):1555-1562. https://doi.org/10.3324/haematol.2009.019299PubMedPubMed CentralGoogle Scholar
- Yamaguchi Y, Moriki T, Igari A. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res. 2011; 128(2):169-173. https://doi.org/10.1016/j.thromres.2011.03.010PubMedGoogle Scholar
- Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 2010; 115(8):1640-1649. https://doi.org/10.1182/blood-2009-06-229203PubMedPubMed CentralGoogle Scholar
- Thomas MR, de Groot R, Scully MA, Crawley JT. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. EBioMedicine. 2015; 2(8):940-950. https://doi.org/10.1016/j.ebiom.2015.06.007PubMedPubMed CentralGoogle Scholar
- Graça NGA, Ercig B, Velásquez Pereira LC. Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura. Haematologica. 2020; 105(11):2619-2630. Google Scholar
- Pos W, Sorvillo N, Fijnheer R. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica. 2011; 96(11):1670-1677. https://doi.org/10.3324/haematol.2010.036327PubMedPubMed CentralGoogle Scholar
- Jian C, Xiao J, Gong L. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2012; 119(16):3836-3843. https://doi.org/10.1182/blood-2011-12-399501PubMedPubMed CentralGoogle Scholar
- Scully M, McDonald V, Cavenagh J. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011; 118(7):1746-1753. https://doi.org/10.1182/blood-2011-03-341131PubMedGoogle Scholar
- Hie M, Gay J, Galicier L. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014; 124(2):204-210. https://doi.org/10.1182/blood-2014-01-550244PubMedGoogle Scholar
- Westwood JP, Thomas M, Alwan F. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017; 1(15):1159-1166. https://doi.org/10.1182/bloodadvances.2017008268PubMedPubMed CentralGoogle Scholar
Figures & Tables
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.